ClinicalTrials.gg
Not yet recruitingNCT07611994COTICHLOUpdated Jun 1, 2026

Analysis of Chlordecone Tissue Concentrations in Patients Treated for Thyroid Surgery at Guadeloupe University Hospital

An interventional study of Blood and thyroid tissue collection in Thyroid and Parathyroid Surgery, sponsored by Centre Hospitalier Universitaire de la Guadeloupe. Not yet recruiting at 1 site in Guadeloupe. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Centre Hospitalier Universitaire de la Guadeloupe · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
69
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Chlordecone, an organochlorine pesticide used in the French Caribbean for several decades, is recognized as an endocrine disruptor. Accumulation in thyroid tissue may be modeled using several factors, including blood chlordecone levels, environmental exposure associated with place of residence, and dietary habits.

Read the detailed description

Chlordecone, an organochlorine pesticide, is recognized as an endocrine disruptor. Following ingestion, this molecule is preferentially stored in the liver and, to a lesser extent, in adipose tissue. The development of thyroid goiter may be promoted by exposure to certain substances. Environmental pollutants have been shown to increase TSH secretion, and prolonged exposure to endocrine disruptors affecting the pituitary-thyroid axis has been associated with thyroid neoplasia.

Currently, exposure to chlordecone is assessed through measurement of chlordeconemia (plasma concentration), reflecting exposure during the months preceding sampling and providing an estimate of body burden at the time of assessment. However, chlordecone impregnation in thyroid tissue and adjacent structures has not yet been investigated in humans.

The aim of this study is to model chlordecone concentration in tissues using chlordeconemia, occupational activity, dietary habits, and place of residence.

A biological collection will be established and stored at the Biological Resources Center (CRB) of the University Hospital to support the primary and secondary objectives. Blood, adipose tissue, and thyroid tissue samples will be collected.

The inclusion period will last 11 months, each participant will be involved for 4 months, and the total study duration will be 16 months.

02

Conditions studied

  • Thyroid and Parathyroid Surgery

Browse trials for

Keywords

  • chlordecone
  • thyroid nodes
  • thyroid disruptor
03

In context

Thyroid Diseases

365 studies on the registry are indexed under Thyroid Diseases; 80 are open to participants now.

This study's planned enrollment of 69 is below the median of 88 across 198 interventional studies indexed under Thyroid Diseases.

Browse Thyroid Diseases studies →

Lead sponsor

Centre Hospitalier Universitaire de la Guadeloupe is the lead sponsor of 50 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients hospitalized at the Guadeloupe University Hospital for surgical treatment of thyroid pathology
  • person affiliated to or beneficiaries of a social security system
  • person with free, informed, and written consent signed by the participant and the investigator

Exclusion criteria

Exclusion Criteria:

  • patients subject to a judicial safeguard measure,
  • patient under 18 years old
  • patient without signed consent
  • current pregnancy at the time of inclusion
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
69 participants (estimated)

Study arms

  • Other
    Participants undergoing thyroid surgery

    Participants undergoing thyroid surgery with prospective collection of blood, thyroid tissue, and adjacent adipose tissue samples for chlordecone concentration assessment and evaluation of exposure-related factors.

    Other: Blood and thyroid tissue collection

Interventions

  • OtherBlood and thyroid tissue collection

    Collection of blood, thyroid tissue, and adjacent adipose tissue samples during routine thyroid surgery for measurement of chlordecone concentration and assessment of exposure-related factors.

06

What researchers measure

Primary outcomes

  1. chlordecone concentration in the adipose tissue adjacent to the thyroid

    Chlordecone concentration measured in adipose tissue adjacent to the thyroid collected during thyroid surgery.

    Time frame: During surgery

  2. Chlordecone concentration in blood

    Chlordecone concentration measured in blood samples collected one day before surgery.

    Time frame: 1 day before surgery

Secondary outcomes

  1. Occupational exposure category

    Occupational activity classified as high or low potential exposure to chlordecone based on professional activity collected through a self-administered questionnaire. Agricultural workers and livestock breeders will be classified as high exposure occupations

    Time frame: At enrollment

  2. Residential environmental exposure assessment

    Environmental exposure assessment based on residential history during the previous 10 years. Residential addresses reported for periods longer than 3 months will be geolocated and linked to soil contamination maps established by CIRAD.

    Time frame: At enrollment

  3. Dietary exposure assessment

    Dietary habits assessed using a self-administered questionnaire collecting information on food consumption patterns and food origin.

    Time frame: At enrollment

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07611994
Lead sponsor
Centre Hospitalier Universitaire de la Guadeloupe
Collaborators
Institut Pasteur de Guadeloupe
Responsible party
Sponsor
First posted
May 28, 2026
Start date
Jul 1, 2026 (estimated)
Primary completion
Nov 1, 2027 (estimated)
Completion
Nov 1, 2027 (estimated)
Last update
Jun 1, 2026

Study contacts

mélanie petapermal, Master degree
Contact
melanie.petapermal@chu-guadeloupe.fr
+590590934667 ext. +590
suzy Duflo, MD PhD
principal investigator · CHU de la Guadeloupe

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion